Stock listing
BOATS:EVGN Evogene Ltd. Stock
US listing (BOATS) of Evogene Ltd. · home listing NASDAQ:EVGN
Follow Evogene Ltd. into a list and get an email when it puts out news.
Home listing price · NASDAQ:EVGN
$0.316 USD -0.034 (-9.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:EVGN
- Day range
- $0.289 – $0.341 USDNov 20, 2026
- Volume
- 62,775 sharesNov 20, 2026
- Market cap
- $4.30M USDAt the close on Nov 20, 2026 · price × 13.59M shares outstanding
- 52-week range
- $0.250 – $1.260 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $567,807 USDMedian day 76,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:EVGN · Home | $0.316 USD | -0.034 (-9.7%) | 62,775 | $0.310 | $0.341 | $0.289 | $0.350 | Close on Nov 20, 2026 |
| TASE:EVGN | 100.20 ILA (agorot) | -14.70 (-12.8%) | 104,056 | 111.10 | 111.10 | 100.20 | 114.90 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:EVGN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.316 | -0.034 | -9.7% | $0.310 | $0.341 | $0.289 | 62,775 | |
| $0.350 | +0.010 | +2.9% | $0.345 | $0.376 | $0.343 | 64,629 | |
| $0.340 | -0.052 | -13.2% | $0.382 | $0.391 | $0.330 | 250,785 | |
| $0.392 | +0.021 | +5.6% | $0.380 | $0.440 | $0.365 | 147,837 | |
| $0.371 | +0.010 | +2.8% | $0.368 | $0.389 | $0.360 | 62,593 | |
| $0.361 | -0.034 | -8.7% | $0.361 | $0.370 | $0.354 | 48,996 | |
| $0.395 | +0.023 | +6.3% | $0.345 | $0.430 | $0.334 | 372,129 | |
| $0.372 | +0.085 | +29.4% | $0.284 | $0.415 | $0.280 | 2,364,146 | |
| $0.288 | +0.017 | +6.5% | $0.265 | $0.300 | $0.265 | 132,797 | |
| $0.270 | -0.060 | -18.2% | $0.280 | $0.280 | $0.250 | 405,100 | |
| $0.330 | -0.030 | -8.3% | $0.340 | $0.340 | $0.300 | 7,677,200 | |
| $0.360 | 0.000 | 0.0% | $0.350 | $0.360 | $0.350 | 12,600 | |
| $0.360 | 0.000 | 0.0% | $0.360 | $0.390 | $0.350 | 23,200 | |
| $0.360 | -0.010 | -2.7% | $0.370 | $0.370 | $0.360 | 22,700 | |
| $0.370 | -0.010 | -2.6% | $0.380 | $0.380 | $0.370 | 14,700 | |
| $0.380 | +0.010 | +2.7% | $0.360 | $0.380 | $0.360 | 13,600 | |
| $0.370 | +0.010 | +2.8% | $0.360 | $0.390 | $0.350 | 40,400 | |
| $0.360 | -0.010 | -2.7% | $0.360 | $0.360 | $0.350 | 9,400 | |
| $0.370 | +0.010 | +2.8% | $0.370 | $0.370 | $0.360 | 39,600 | |
| $0.360 | -0.020 | -5.3% | $0.370 | $0.370 | $0.360 | 9,100 | |
| $0.380 | +0.010 | +2.7% | $0.360 | $0.390 | $0.360 | 10,100 | |
| $0.370 | 0.000 | 0.0% | $0.370 | $0.380 | $0.370 | 38,000 | |
| $0.370 | 0.000 | 0.0% | $0.390 | $0.390 | $0.370 | 11,100 | |
| $0.370 | -0.020 | -5.1% | $0.380 | $0.390 | $0.350 | 117,600 | |
| $0.390 | -0.010 | -2.5% | $0.410 | $0.410 | $0.380 | 38,100 | |
| $0.400 | +0.020 | +5.3% | $0.380 | $0.400 | $0.380 | 27,100 | |
| $0.380 | -0.010 | -2.6% | $0.380 | $0.390 | $0.370 | 52,600 | |
| $0.390 | 0.000 | 0.0% | $0.390 | $0.400 | $0.370 | 87,600 | |
| $0.390 | +0.010 | +2.6% | $0.390 | $0.400 | $0.380 | 106,200 | |
| $0.380 | -0.020 | -5.0% | $0.390 | $0.390 | $0.370 | 105,900 | |
| $0.400 | -0.010 | -2.4% | $0.390 | $0.410 | $0.380 | 88,300 | |
| $0.410 | -0.010 | -2.4% | $0.430 | $0.430 | $0.390 | 82,300 | |
| $0.420 | +0.020 | +5.0% | $0.390 | $0.440 | $0.390 | 625,200 | |
| $0.400 | -0.030 | -7.0% | $0.410 | $0.410 | $0.370 | 592,900 | |
| $0.430 | -0.010 | -2.3% | $0.410 | $0.450 | $0.410 | 142,500 | |
| $0.440 | +0.040 | +10.0% | $0.380 | $0.470 | $0.380 | 821,600 | |
| $0.400 | -0.010 | -2.4% | $0.390 | $0.420 | $0.350 | 9,991,200 | |
| $0.410 | +0.030 | +7.9% | $0.370 | $0.470 | $0.360 | 60,317,200 | |
| $0.380 | -0.040 | -9.5% | $0.410 | $0.450 | $0.350 | 170,800 | |
| $0.420 | 0.000 | 0.0% | $0.420 | $0.480 | $0.420 | 76,500 | |
| $0.420 | -0.030 | -6.7% | $0.450 | $0.490 | $0.420 | 284,000 | |
| $0.450 | -0.040 | -8.2% | $0.490 | $0.490 | $0.440 | 114,900 | |
| $0.490 | +0.030 | +6.5% | $0.480 | $0.500 | $0.460 | 30,200 | |
| $0.460 | -0.040 | -8.0% | $0.520 | $0.520 | $0.460 | 131,000 | |
| $0.500 | 0.000 | 0.0% | $0.500 | $0.500 | $0.470 | 18,000 | |
| $0.500 | 0.000 | 0.0% | $0.500 | $0.500 | $0.490 | 30,500 | |
| $0.500 | -0.030 | -5.7% | $0.510 | $0.510 | $0.470 | 65,200 | |
| $0.530 | +0.040 | +8.2% | $0.480 | $0.530 | $0.480 | 154,300 | |
| $0.490 | +0.010 | +2.1% | $0.480 | $0.510 | $0.470 | 112,800 | |
| $0.480 | 0.000 | 0.0% | $0.470 | $0.500 | $0.450 | 2,459,500 | |
| $0.480 | -0.020 | -4.0% | $0.500 | $0.510 | $0.480 | 41,700 | |
| $0.500 | -0.010 | -2.0% | $0.520 | $0.530 | $0.500 | 25,700 | |
| $0.510 | -0.030 | -5.6% | $0.550 | $0.550 | $0.500 | 156,700 | |
| $0.540 | -0.010 | -1.8% | $0.540 | $0.550 | $0.520 | 62,800 | |
| $0.550 | +0.010 | +1.9% | $0.550 | $0.550 | $0.540 | 28,600 | |
| $0.540 | +0.020 | +3.8% | $0.530 | $0.550 | $0.530 | 36,400 | |
| $0.520 | -0.020 | -3.7% | $0.530 | $0.540 | $0.520 | 31,300 | |
| $0.540 | -0.010 | -1.8% | $0.550 | $0.550 | $0.510 | 161,900 | |
| $0.550 | +0.010 | +1.9% | $0.560 | $0.560 | $0.540 | 15,200 | |
| $0.540 | 0.000 | 0.0% | $0.550 | $0.560 | $0.530 | 59,500 | |
| $0.540 | -0.010 | -1.8% | $0.540 | $0.550 | $0.520 | 74,600 | |
| $0.550 | -0.010 | -1.8% | $0.560 | $0.560 | $0.530 | 113,300 | |
| $0.560 | 0.000 | 0.0% | $0.570 | $0.580 | $0.550 | 191,000 | |
| $0.560 | 0.000 | 0.0% | $0.540 | $0.580 | $0.540 | 1,033,800 | |
| $0.560 | -0.040 | -6.7% | $0.600 | $0.600 | $0.550 | 228,300 |
Splits
1 split · NASDAQ:EVGN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- BOATS:EVGN
- Asset type
- Stock
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs
Latest earnings call · Nov 19, 2026
Evogene (NASDAQ:EVGN) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 27, 2026
Investor Presentation (August 2026)
Investor deck · 32 slides
Latest news
Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs
Nov 19, 2026
Closed $0.316 (-9.7%) on Nov 20, 2026
AgPlenus Announces Significant Progress in Its Fungicide Discovery Programs Targeting New Modes of Action, with Activity Against Resistant Septoria and Additional Fungal Pathogens
Nov 17, 2026
Closed $0.34 (-13.2%) on Nov 17, 2026
Evogene Schedules Third Quarter 2026 Financial Results Release
Nov 5, 2026
Closed $0.33 (-8.3%) on Nov 5, 2026
Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program
Oct 28, 2026
Closed $0.37 (+2.8%) on Oct 28, 2026
Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain
Oct 26, 2026
Closed $0.37 (+2.8%) on Oct 26, 2026
Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL
Oct 20, 2026
Closed $0.37 (0.0%) on Oct 20, 2026
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
Oct 6, 2026
Closed $0.41 (-2.4%) on Oct 7, 2026
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
Sep 30, 2026
Closed $0.40 (-2.4%) on Sep 30, 2026
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
Aug 31, 2026
Closed $0.54 (-1.8%) on Aug 31, 2026
Evogene Ltd. on 6ix
- News releases
- 36 in the last 12 months · 114 in all · newest Nov 19, 2026 · oldest 2019
- Calls
- 28 calls with a replay · 28 with a transcript · latest Nov 19, 2026
- Decks
- 53 decks · latest Aug 27, 2026
Where Evogene Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:EVGN · Home listing | NASDAQ | United States | USD |
| TASE:EVGN | TASE | Israel | ILA |
| BOATS:EVGN · This page | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$3.06M USD
- P/E
- Loss
- EV/sales
- −2.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- −166.6%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.39
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 2.15 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.10 · 1 analyst
- Revenue, year to Dec 2026
- 1.44M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Richard Novak | CEO, Unravel Biosciences |
| Sven Wichert | CEO of Systasy Bioscience |
Board
| Director | Role |
|---|---|
| Nir Nimrodi | Chairperson of the Board |
| Adrian Percy | Board Member |
| Dan Falk | Board Member |
| Leon Recanati | Board Member |
| Ofer Haviv | Board Member |
| Sarit Firon | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Evogene (NASDAQ:EVGN) Q3 2026 Earnings Call | Thu, Nov 19, 2026 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q2 2026 Earnings Call | Tue, Aug 18, 2026 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q1 2026 Earnings Call | Wed, May 20, 2026 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q4 2025 Earnings Call | Thu, Mar 05, 2026 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q3 2025 Earnings Call | Thu, Nov 20, 2025 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q2 2025 Earnings Call | Tue, Aug 19, 2025 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q1 2025 Earnings Call | Wed, May 21, 2025 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q4 2024 Earnings Call | Thu, Mar 06, 2025 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q3 2024 Earnings Call | Thu, Nov 21, 2024 · 9:00 AM ET | Replay |
| Evogene (NASDAQ:EVGN) Q2 2024 Earnings Call | Thu, Aug 22, 2024 · 9:00 AM ET | Replay |
All 28 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 19, 2026 · Before open | −9.7% |
| Q2 2026 | Aug 18, 2026 · Before open | +3.6% |
| Q1 2026 | May 20, 2026 · Before open | −2.7% |
| Q4 2025 | Mar 5, 2026 | −8.3% |
| Q3 2025 | Nov 20, 2025 · Before open | −7.7% |
| Q2 2025 | Aug 19, 2025 · Before open | −4.5% |
| Q1 2025 | May 21, 2025 · Before open | −6.3% |
| Q4 2024 | Mar 5, 2025 · After close | 0.0% |
| Q3 2024 | Nov 21, 2024 · Before open | −3.0% |
| Q2 2024 | Aug 22, 2024 · Before open | −10.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 23, 2024 · Before open | −2.7% |
| Q4 2023 | Mar 7, 2024 · Before open | +3.2% |
| Q3 2023 | Nov 15, 2023 · Before open | +4.8% |
| Q2 2023 | Aug 17, 2023 · Before open | −19.2% |
| Q1 2023 | May 18, 2023 · Before open | −4.5% |
| Q4 2022 | Mar 9, 2023 · Before open | −4.2% |
| Q3 2022 | Nov 17, 2022 · Before open | +1.4% |
| Q2 2022 | Aug 31, 2022 · Before open | −13.3% |
| Q1 2022 | May 26, 2022 · Before open | −8.2% |
| Q4 2021 | Mar 10, 2022 · Before open | +7.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 32 slides | Aug 27, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 18 slides | Aug 18, 2026 |
| Investor Presentation (June 2026) | Investor deck | 32 slides | Jun 16, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 27 slides | May 20, 2026 |
| Investor Presentation (April 2026) | Investor deck | 27 slides | Apr 28, 2026 |
| Investor Presentation (March 2026) | Investor deck | 26 slides | Mar 12, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 18 slides | Mar 5, 2026 |
| Investor Presentation (January 2026) | Investor deck | 29 slides | Jan 7, 2026 |
| Investor Presentation (November 2025) | Investor deck | 28 slides | Nov 27, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 34 slides | Nov 20, 2025 |
Show 50 decks
This page holds 50 of 53 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Warrant exercise of ordinary shares on exercise of August 2024 Series A and Series B warrants Announced: about US$3.4M · US$1 a share · Warrants at US$1.25 · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners Use of proceeds: Working capital and other general corporate purposes | Feb 10, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$14.75 a share on Nov 20, 2013.
- Price
- US$14.75 a share
- Shares offered
- 5,000,000 ordinary shares
- Offering size
- US$73.8 million
- Underwriters' option
- Up to 750,000 more shares
- Underwriters
- Credit Suisse, Deutsche Bank Securities, Oppenheimer & Co., Piper Jaffray · In the order on the cover
- Shares delivered
- On or about Nov 26, 2013
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 26, 2013 |
| Filed publicly | Sep 23, 2013 |
| Amended 6 times | Newest Nov 19, 2013 |
| Shares registered with an exchange | Nov 8, 2013 |
| Declared effective by the SEC | Nov 20, 2013 |
| Final prospectus, with the price | Nov 22, 2013 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 22, 2013 |
| EFFECT · Notice that a registration is effective | Nov 20, 2013 |
| F-1/A · Registration statement, amended | Nov 19, 2013 |
| CORRESP · Letter to the SEC | Nov 18, 2013 |
| F-1/A · Registration statement, amended | Nov 15, 2013 |
| UPLOAD · Letter from the SEC | Nov 15, 2013 |
| CERTNYS · New York Stock Exchange's certificate of listing | Nov 12, 2013 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 8, 2013 |
| CORRESP · Letter to the SEC | Nov 6, 2013 |
| F-1/A · Registration statement, amended | Nov 6, 2013 |
All 30 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Nov 6, 2013 |
| F-1/A · Registration statement, amended | Oct 31, 2013 |
| CORRESP · Letter to the SEC | Oct 28, 2013 |
| F-1/A · Registration statement, amended | Oct 28, 2013 |
| UPLOAD · Letter from the SEC | Oct 21, 2013 |
| CORRESP · Letter to the SEC | Oct 11, 2013 |
| F-1/A · Registration statement, amended | Oct 11, 2013 |
| UPLOAD · Letter from the SEC | Oct 7, 2013 |
| F-1 · Registration statement | Sep 23, 2013 |
| UPLOAD · Letter from the SEC | Sep 5, 2013 |
| DRSLTR · Letter to the SEC with a draft | Aug 22, 2013 |
| DRS/A · Draft registration statement, amended | Aug 22, 2013 |
| UPLOAD · Letter from the SEC | Jul 24, 2013 |
| DRSLTR · Letter to the SEC with a draft | Jul 11, 2013 |
| DRS/A · Draft registration statement, amended | Jul 11, 2013 |
| UPLOAD · Letter from the SEC | Jun 18, 2013 |
| DRSLTR · Letter to the SEC with a draft | Jun 3, 2013 |
| DRS/A · Draft registration statement, amended | Jun 3, 2013 |
| UPLOAD · Letter from the SEC | May 23, 2013 |
| DRS · Draft registration statement | Apr 26, 2013 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 22, 2013
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.85M | 5.58M | 2.98M | 1.68M | 930.0K | 1.04M | 753.0K | 1.75M | 3.38M | 6.54M |
| Cost of revenue | 4.09M | 2.38M | 1.49M | 909.0K | 767.0K | 574.0K | 334.0K | 1.45M | 2.85M | 5.64M |
| Gross profit | -241.0K | 3.20M | 1.49M | 766.0K | 163.0K | 466.0K | 419.0K | 295.0K | 536.0K | 901.0K |
| Research and development | 7.99M | 12.5M | 16.2M | 20.8M | 21.1M | 17.3M | 15.8M | 14.7M | 17.0M | 16.4M |
| Selling, general and administrative | 4.29M | 6.99M | 5.38M | 6.48M | 7.25M | 5.32M | 3.77M | 3.51M | 3.81M | 3.89M |
| Operating income | -14.0M | -18.8M | -22.2M | -26.9M | -31.0M | -24.8M | -21.2M | -20.0M | -21.9M | -21.1M |
| Depreciation and amortization | 1.14M | 1.38M | 1.30M | 1.51M | 1.30M | 1.79M | 2.40M | 2.02M | 2.15M | 2.28M |
| EBITDA | -12.9M | -17.4M | -20.9M | -25.4M | -29.7M | -23.0M | -18.8M | -18.0M | -19.8M | -18.8M |
| Interest expense | 1.93M | 3.36M | 928.0K | 3.33M | 1.41M | 2.95M | 555.0K | 2.21M | 1.00M | 891.0K |
| Income before tax | -13.5M | -14.8M | -21.9M | -29.8M | -30.4M | -26.2M | -19.1M | -20.8M | -20.8M | -19.6M |
| Income tax | 1.00K | 9.00K | 19.0K | 90.0K | 13.0K | 32.0K | 24.0K | 30.0K | 11.0K | 36.0K |
| Net income | -8.48M | -16.5M | -23.9M | -26.6M | -27.8M | -23.4M | -18.1M | -20.8M | -20.8M | -19.6M |
| Earnings per share, basic | 1.08 | -2.90 | -5.20 | -6.44 | -0.69 | -0.83 | -0.70 | -0.81 | -0.81 | -0.77 |
| Earnings per share, diluted | 1.08 | -2.90 | -5.20 | -6.44 | -0.69 | -0.83 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 13.0M | 15.3M | 20.8M | 29.0M | 32.3M | 46.2M | 34.7M | 5.81M | 3.44M | 3.24M |
| Short-term investments | 32.0K | 10.0K | 10.3M | 6.38M | 21.5M | 2.00M | 12.1M | 48.7M | 68.3M | 84.9M |
| Receivables | 317.0K | 1.09M | 357.0K | 348.0K | 281.0K | 222.0K | 72.0K | 160.0K | 132.0K | 169.0K |
| Inventory | 210.0K | 1.82M | 76.0K | 566.0K | 92.0K | 0 | -894.0K | -444.0K | -8.33M | -13.1M |
| Current assets | 15.6M | 21.6M | 34.5M | 37.8M | 56.9M | 51.8M | 49.0M | 55.5M | 72.8M | 89.5M |
| Property, plant and equipment | 812.0K | 1.80M | 2.46M | 2.50M | 2.07M | 2.07M | 2.58M | 3.19M | 4.79M | 6.48M |
| Total assets | 20.0M | 39.9M | 51.1M | 56.1M | 76.3M | 71.9M | 71.4M | 58.7M | 77.6M | 96.0M |
| Accounts payable | 639.0K | 1.23M | 1.78M | 1.04M | 1.46M | 863.0K | 1.00M | 1.01M | 1.11M | 1.33M |
| Current liabilities | 3.44M | 18.7M | 6.94M | 5.63M | 6.88M | 9.68M | 5.75M | 5.43M | 4.66M | 5.22M |
| Long-term debt | 10.4M | 10.1M | ||||||||
| Total debt | 2.20M | 12.9M | 11.5M | 11.9M | 2.67M | 2.44M | 2.97M | |||
| Total liabilities | 8.07M | 25.0M | 22.4M | 21.3M | 12.9M | 15.0M | 11.1M | 8.39M | 8.22M | 8.70M |
| Shareholders' equity | -82.0K | -1.45M | 12.1M | 27.9M | 53.7M | 46.0M | 50.1M | 50.1M | 69.4M | 87.3M |
| Shares outstanding | 8.72M | 6.51M | 5.08M | 41.3M | 41.2M | 35.6M | 25.8M | 25.8M | 25.8M | 25.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -13.5M | -19.7M | -21.6M | -23.7M | -24.7M | -19.5M | -17.7M | -15.2M | -15.9M | -11.7M |
| Capital spending | -135.0K | -626.0K | -577.0K | -1.17M | -847.0K | -682.0K | -900.0K | -374.0K | -590.0K | -808.0K |
| Free cash flow | -13.6M | -20.3M | -22.2M | -24.8M | -25.6M | -20.2M | -18.6M | -15.5M | -16.5M | -12.5M |
| Cash from investing | 17.7M | 9.62M | -4.54M | 13.3M | -20.6M | 9.41M | 37.1M | 17.4M | 15.2M | 4.03M |
| Cash from financing | -6.60M | 4.66M | 18.2M | 9.34M | 30.3M | 20.4M | 9.31M | 297.0K | 814.0K | 655.0K |
| Share buybacks | 10.0M | 9.00K | 683.0K | 186.0K | ||||||
| Change in cash | -2.35M | -5.47M | -8.21M | -3.35M | -13.9M | 11.5M | 28.9M | 2.38M | 199.0K | -6.99M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 10, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 28, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 22, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 22, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 6, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Oct 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
Show 200 filings
This page holds 200 of 467 filings. Open Filings
Cap table
Built by 6ix from Evogene Ltd.’s releases · as of Sep 30, 2026
- Common shares
- 13,586,507
- Fully diluted
- 13,586,507
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 13,586,507 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 13,586,507 |
| Sep 30, 2026 | 18,052,405 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dan Falk Other companies: Innoviz Technologies Ltd. (Director · Since at least Mar 18, 2026); NICE Ltd. (Director · Since at least Mar 18, 2026) | Board Member · Since at least Mar 18, 2026 |
| Nir Nimrodi Other companies: Odysight.ai Inc. (Director · Since at least Feb 10, 2025); Precigen, Inc. (Chief Business Officer · Mar 17, 2014 – Jan 4, 2019 · Past) | Chairperson of the Board · Since at least Mar 18, 2026 |
| Leon Recanati Other companies: Kamada Ltd. (Director · Since at least Mar 16, 2026) | Board Member · Since at least Mar 18, 2026 |
| Sarit Firon Other companies: MediaMind Technologies Inc (Chief Financial Officer · Aug 10, 2010 – Aug 10, 2010 · Past) | Board Member · Since at least Mar 6, 2025 |
| Yaron Eldad Other companies: Freightos Limited (Chief Financial Officer · Since at least Aug 17, 2026) | Chief Financial Officer · Since at least Mar 18, 2026 |
| Adrian Percy | Board Member · Since at least Mar 18, 2026 |
| Gabi Tarcic | Chief Development Officer · Since at least Mar 18, 2026 |
| Ilia Zhidkov | Chief Technology Officer · Since at least Mar 18, 2026 |
| Ofer Haviv | Board Member · Since at least Mar 18, 2026 |
| Olga Nissan | Vice President of Business Development · Dec 30, 2025 – Nov 5, 2026 · Past |
All 13 people
| Person | Seat |
|---|---|
| Polina Ravzin | VP Finance · Since at least Apr 1, 2026 |
| Richard Novak | CEO, Unravel Biosciences · Since at least Jan 7, 2026 |
| Sven Wichert | CEO of Systasy Bioscience · Since at least Feb 11, 2026 |
Log in to ask 6ix AI your own questions about Evogene Ltd.